4Q 2018 Results and preliminary annual report

01. Mar 2019 | 1 min read

Moss, 28 February 2019
 
Gentian Diagnostics AS announces its results for the 4th quarter and 2018 preliminary annual results. The highlights include:
 
  • Record sales revenues of MNOK 11.1 for the quarter
  • 42 % growth in underlying sales revenue compared to 4Q17, 43 % year to date
  • All time high sales results achieved with fCAL® turbo

 

 
Please find the report here:  GDAS 2018 4Q Interim report[2594] or on Oslo Børs NewsWeb.
 
For further information, please contact:
 
Hilja Ibert
CEO, Gentian Diagnostics
E-mail: hilja.ibert@gentian.no
Cell Phone: +47 919 05 242
 
Njaal Kind
CFO, Gentian Diagnostics
E-mail: njaal.kind@gentian.no
Cell Phone. +47 919 06 525

You may also read


Feb 12, 2026 - Ole Sørlie

Gentian Diagnostics: Key information relating to the proposed cash dividend

Moss, 12 February 2026 The Board of Directors of Gentian Diagnostics ASA proposes a dividend of NOK 0.60 per..

Read more

Feb 11, 2026 - Ole Sørlie

Update on the development of the NT-proBNP assay

Gentian Diagnostics ASA announces an update on the development of its NT proBNP assay. Recent investigations..

Read more

Feb 11, 2026 - Ole Sørlie

Gentian Diagnostics: Fourth quarter 2025 report

Moss, 11 February 2026 Gentian Diagnostics ASA, a fast-growing developer and manufacturer of diagnostic..

Read more